These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34539621)

  • 1. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
    Front Immunol; 2021; 12():663602. PubMed ID: 34539621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
    Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
    Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
    Karpe KM; Talaulikar GS; Walters GD
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
    Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
    Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
    Su L; Tam N; Deng R; Chen P; Li H; Wu L
    Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
    Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
    Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.
    Hasbal NB; Turgut D; Gok Oguz E; Ulu S; Gungor O
    Ann Transplant; 2021 Mar; 26():e929279. PubMed ID: 33707409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
    Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
    Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.